Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
01 Ottobre 2024 - 3:20PM
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage
biotechnology company focused on unlocking the broad potential of
RNA medicines to transform human health, announced today that it
closed its previously announced underwritten public offering, and
that the underwriters exercised in full their option to purchase an
additional 3,750,000 of its ordinary shares at the public offering
price of $8.00 per ordinary share, less underwriting discounts and
commissions. After giving effect to the full exercise of the
underwriters’ option to purchase additional shares, the total
number of ordinary shares sold in the offering is 26,875,001
ordinary shares which, along with the sale of pre-funded warrants
to purchase 1,875,023 ordinary shares, resulted in aggregate gross
proceeds to Wave Life Sciences of approximately $230 million,
before deducting underwriting discounts and commissions and
offering expenses.
J.P. Morgan and Leerink Partners acted as joint
book-running managers for the offering. Truist Securities and
Mizuho acted as book-runners for the offering.
The offering was made only by means of a
prospectus and related prospectus supplement forming part of a
shelf registration statement that was previously filed with and
declared effective by the Securities and Exchange Commission
(“SEC”). The final prospectus supplement and accompanying base
prospectus relating to the offering were filed with the SEC on
September 27, 2024 and are available on the SEC’s website located
at http://www.sec.gov, copies of which may be obtained from J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by email at
prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com; or from Leerink Partners
LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, or by telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@leerink.com.
This press release shall not constitute an offer
to sell, or a solicitation of an offer to buy, nor will there be
any sale of these securities in any state or other jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a
biotechnology company focused on unlocking the broad potential of
RNA medicines to transform human health. Wave’s RNA medicines
platform, PRISM®, combines multiple modalities, chemistry
innovation and deep insights in human genetics to deliver
scientific breakthroughs that treat both rare and prevalent
disorders. Its toolkit of RNA-targeting modalities includes
editing, splicing, RNA interference and antisense silencing,
providing Wave with unmatched capabilities for designing and
sustainably delivering candidates that optimally address disease
biology. Wave’s diversified pipeline includes clinical programs in
Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and
Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, Wave is leading the
charge toward a world in which human potential is no longer
hindered by the burden of disease. Wave is headquartered
in Cambridge, MA.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended. The words “may,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,”
“believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
statements are subject to various risks and uncertainties, actual
results could differ materially from those projected and Wave
cautions investors not to place undue reliance on the
forward-looking statements in this press release. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, the risks and
uncertainties described in the section entitled “Risk Factors” in
Wave’s final prospectus supplement related to the offering filed
with the SEC on September 27, 2024 and Wave’s most recent Annual
Report on Form 10-K filed with the SEC, as amended, and in other
filings Wave makes with the SEC from time to time. Wave undertakes
no obligation to update the information contained in this press
release to reflect subsequently occurring events or
circumstances.
Investor Contact:Kate Rausch+1
617-949-4827krausch@wavelifesci.com
Media Contact:Alicia Suter+1
617-949-4817asuter@wavelifesci.com
Grafico Azioni Wave Life Sciences (NASDAQ:WVE)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Wave Life Sciences (NASDAQ:WVE)
Storico
Da Dic 2023 a Dic 2024